SWOG clinical trial number
R9811

Phase III Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal

Closed
Phase
Published
Abbreviated Title
RECTAL
Activated
03/01/2001
Closed
06/27/2005
Participants
NCORP, Members, Radiation Oncologists, Surgeons

Research committees

Gastrointestinal Cancer

Treatment

Cisplatin 5-Fluorouracil Mitomycin-C Radiation Therapy Surgery

Eligibility Criteria Expand/Collapse

Histologically proven primary squamous, baseloid, or cloacogenic carcinoma of the anal canal. KPS 3 60; T stage 2 - 4. Adequate hepatic, renal and bone marrow function. No prior radiation or chemotherapy; no surgery except for biopsy at study site. Patients with AIDS are not eligible.

Publication Information Expand/Collapse

2013

Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial

LL Gunderson;J Moughan;JA Ajani;JE Pedersen;KA Winter;AB Benson;CR Thomas;RJ Mayer;MG Haddock;T Rich;CG Willett International Journal of Radiation Oncology, Biology, Physics 87(4):638-645

PMid: PMID24035327 | PMC number: PMC3938865

2012

Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin

L Gunderson;KA Winter;JA Ajani;JE Pedersen;J Moughan;AB Benson;CR Thomas;RJ Mayer;MG Haddock;TA Rich;CG Willett Journal of Clinical Oncology 30(35):4344-4351;

PMid: PMID23150707 | PMC number: PMC3515768

2010

Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).

A Ajani;KA Winter;LL Gunderson;J Pedersen;A Benson;CR Thomas;RJ Mayer;MG Haddock;TA Rich;CG Willett Cancer Sep 1;116(17):4007-4013

PMid: PMID20564111 | PMC number: PMC3831519

2009

US intergroup anal carcinoma trial: tumor diameter predicts for colostomy [PMID19138424; PMC2667813]

JA Ajani;KA Winter;LL Gunderson;J Pederson;AB Benson;CR Thomas;RJ Mayer;MG Haddock;TA Rich;CG Willett Journal of Clinical Oncology 27(7):1116-1121

2008

Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherappy for carcinoma of the anal canal: a randomized controlled trial. [PMID18430910]

JA Ajani;KA Winter;LL Gunderson;J Pedersen;AB Benson;CR Thomas;RJ Mayer;MG Haddock;TA Rich;C Willett Journal of the American Medical Association 299(16):1914-1921

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
83%
Open
Phase